Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. 2002

Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, 401 College Street, Richmond, VA 23298-0058, USA.

Prolonged activation of the mitogen-activated protein kinase (MAPK) pathway enhances expression of the cyclin kinase inhibitor p21 that can promote growth arrest and cell survival in response to cytotoxic insults. Bile acids can also cause prolonged MAPK activation that is cytoprotective against bile acid-induced cell death. Here, we examined the impact of bile acid-induced MAPK signaling and p21 expression on the survival of primary mouse hepatocytes. Deoxycholic acid (DCA) caused prolonged activation of the MAPK pathway that weakly enhanced p21 protein expression. When DCA-induced MAPK activation was blocked using MEK1/2 inhibitors, both hepatocyte viability and expression of p21 were reduced. Surprisingly, constitutive overexpression of p21 in p21+/+ hepatocytes enhanced DCA-induced cell killing. In agreement with these findings, treatment of p21-/- hepatocytes with DCA and MEK1/2 inhibitors also caused less apoptosis than observed in wild-type p21+/+ cells. Expression of p21 in p21-/- hepatocytes did not modify basal levels of apoptosis but restored the apoptotic response of p21-/- cells to those of p21+/+ cells overexpressing p21. These findings suggest that basal expression of p21 plays a facilitating, proapoptotic role in DCA-induced apoptosis. Overexpression of p21 enhanced p53 protein levels. In agreement with a role for p53 in the enhanced apoptotic response, overexpression of p21 did not potentiate apoptosis in p53-/- hepatocytes but, instead, attenuated the death response in these cells. In conclusion, our data suggest that overexpression of p21 can promote apoptosis, leading to elevated sensitivity to proapoptotic stimuli.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003840 Deoxycholic Acid A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent. Deoxycholate,Desoxycholic Acid,Kybella,Choleic Acid,Deoxycholic Acid, 12beta-Isomer,Deoxycholic Acid, 3beta-Isomer,Deoxycholic Acid, 5alpha-Isomer,Deoxycholic Acid, Disodium Salt,Deoxycholic Acid, Magnesium (2:1) Salt,Deoxycholic Acid, Monoammonium Salt,Deoxycholic Acid, Monopotassium Salt,Deoxycholic Acid, Monosodium Salt,Deoxycholic Acid, Sodium Salt, 12beta-Isomer,Dihydroxycholanoic Acid,Lagodeoxycholic Acid,Sodium Deoxycholate,12beta-Isomer Deoxycholic Acid,3beta-Isomer Deoxycholic Acid,5alpha-Isomer Deoxycholic Acid,Deoxycholate, Sodium,Deoxycholic Acid, 12beta Isomer,Deoxycholic Acid, 3beta Isomer,Deoxycholic Acid, 5alpha Isomer
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004792 Enzyme Precursors Physiologically inactive substances that can be converted to active enzymes. Enzyme Precursor,Proenzyme,Proenzymes,Zymogen,Zymogens,Precursor, Enzyme,Precursors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001647 Bile Acids and Salts Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. Bile Acid,Bile Salt,Bile Salts,Bile Acids,Acid, Bile,Acids, Bile,Salt, Bile,Salts, Bile

Related Publications

Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
September 2016, The Journal of biological chemistry,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
September 2008, The Journal of biological chemistry,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
October 2005, Kidney international,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
June 2002, Molecular cancer therapeutics,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
January 2009, The Journal of biological chemistry,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
October 1995, The American journal of pathology,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
July 1997, American journal of obstetrics and gynecology,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
May 2012, The Journal of biological chemistry,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
August 1994, Oncogene,
Liang Qiao, and Robert McKinstry, and Seema Gupta, and Donna Gilfor, and Jolene J Windle, and Philip B Hylemon, and Steven Grant, and Paul B Fisher, and Paul Dent
December 2003, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!